表紙
市場調查報告書

生物相似藥的全球市場:產品、用途、規定

Global Biosimilars Market - Products, Applications and Regulations

出版商 Industry Experts 商品編碼 839490
出版日期 內容資訊 英文 364 Pages, 223 Charts
訂單完成後即時交付
價格
Back to Top
生物相似藥的全球市場:產品、用途、規定 Global Biosimilars Market - Products, Applications and Regulations
出版日期: 2019年05月09日內容資訊: 英文 364 Pages, 223 Charts
簡介

在全球生物醫藥品市場中,單株抗體預計單獨構成最大的產品類型,2018年的需求估計為44億美元,至2025年達到288億美元。預計生物相似藥整體市場規模,2019年達到104億美元。

本報告提供全球生物相似藥醫藥品市場相關調查分析,世界/各地區市場分析及預測,主要企業等相關的系統性資訊。

A部分:全球市場預測

第1章 簡介

第2章 法規形勢

  • 美國食品藥物管理局 (USFDA)
  • 歐洲藥品管理局 (EMA)
  • 世界衛生組織 (WHO)
  • 加拿大
  • 韓國
  • 中國
  • 印度
  • 日本
  • 墨西哥
  • 巴西
  • 阿根廷

第3章 主要市場趨勢

第4章 近幾年的生物仿製藥核准

第5章 全球主要企業

  • Adello Biologics (美國)
  • Amgen Inc. (美國)
  • AXXO GmbH (德國)
  • BIOCAD (俄羅斯)
  • Biogen, Inc. (美國)
  • CoherusBioSciences (美國)
  • Creative BioMart (美國)
  • Dong-A Socio Group (韓國)
  • Dr. Reddy's Laboratories Ltd. (印度)
  • Eli Lilly and Company (美國)
  • Genor Biopharma Co., Ltd. (中國)
  • Hetero Drugs Limited (印度)
  • Insud Pharma SL (西班牙)
  • mAbxience SA (西班牙)
  • Intas Pharmaceuticals Ltd. (印度)
  • LG Chem (韓國)
  • Lupin Limited (印度)
  • Mylan, Inc (美國)
  • Nippon Kayaku Co., Ltd. (日本)
  • Pfizer, Inc. (美國)
  • Reliance Life Sciences Pvt. Ltd. (印度)
  • Sandoz International GmbH (德國)
  • Shanghai Henlius Biotech, Inc. (中國)
  • STADA Arzneimittel AG (德國)
  • Teva Pharmaceutical Industries Limited (以色列)
  • Wockhardt Limited (印度)
  • Zydus Cadila (印度)

第7章 全球市場概要

  • 市場概要:各產品類型
    • 各地區
      • 單株抗體 (moAb)
      • 促血紅細胞生長素
      • 顆粒球集群刺激原因 (G-CSF)
      • 胰島素
      • 其他的產品類型
  • 市場概要:各治療領域
    • 各地區
      • 癌症
      • 自體免疫疾病
      • 血液疾病
      • 生長激素缺乏症
      • 其他的用途

B部分:各地區市場預測

各地區市場概要

第8章 歐洲

  • 市場概要:各地區
  • 市場概要:各產品類型
  • 市場概要:各治療領域
  • 主要企業
  • 各國分析
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 其他的歐洲

第9章 北美

  • 市場概要:各地區
  • 市場概要:各產品類型
  • 市場概要:各治療領域
  • 主要企業
  • 各國分析
    • 美國
    • 加拿大
    • 墨西哥

第10章 亞太地區

  • 市場概要:各地區
  • 市場概要:各產品類型
  • 市場概要:各治療領域
  • 主要企業
  • 各國分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他的亞太地區

第11章 其他地區

  • 市場概要:各產品類型
  • 市場概要:各用途
  • 市場概要:各治療領域
  • 主要企業
  • 各國分析
    • 巴西
    • 以色列
    • 其他各國

C部分:產業指南

D部分:附錄

目錄
Product Code: BT010

Report Synopsis

Cost effectiveness, increasing geriatric population, rising incidences and prevalence of chronic ailments such as Cancer, Autoimmune Disorders and Diabetes and supportive government regulations and guidelines are some of the factors fueling the biosimilars market. Patent expiry of most of the monoclonal antibody based biologics drives the biosimilar monoclonal antibody market. Oncology biosimilar market leads the biosimilars market and is primarily driven by the rising prevalence and incidence of cancer and patent expiry of the expensive biologics. On the other hand, the growth of the biosimilars market is retarded due to insufficient regulatory guidelines, expensive research and development procedures and preference of patented products by the patients, etc.

Monoclonal Antibodies constitute the single largest product type in the global Biosimilars market, demand for which is estimated at US$4.4 billion in 2018 and is projected to reach US$28.8 billion by 2025. The overall Biosimilars market in 2019 is expected to reach US$10.4 billion.

Research Findings & Coverage

  • Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas
  • The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally
  • mAbs - All the Rage in Biosimilars' New Wave
  • Biosimilars Slashes the Cancer Treatment Cost
  • Novel mAb's Purification Approach to Maximize the Biosimilar Production
  • Asia: A Preferred Manufacturing Hub for Biosimilars
  • Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
  • Major companies profiled - 42
  • The industry guide includes the contact details for 151 companies

Product Outline

The report analyzes the market for the following key product types of Biosimilars:

  • Monoclonal Antibodies (mAB)
  • Erythropoietin (EPO)
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Insulin
  • Others (includes Interferons, Follitropins, Recombinant Proteins etc.)

Therapeutic areas of Biosimilars analyzed in this study comprise the following:

  • Oncology
  • Autoimmune Disorders
  • Blood Disorders
  • Growth Hormone Deficiency
  • Others (includes Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)

Analysis Period, Units and Growth Rates

The report reviews, analyzes and projects the global Biosimilars market for the period 2016-2025 in terms of US$ and the compound annual growth rates (CAGRs) projected from 2018 through 2025.

Geographic Coverage

  • North America (The United States, Canada and Mexico)
  • Europe (Germany, the United Kingdom, France, Spain, Italy and Rest of Europe)
  • Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)
  • Rest of World (Brazil, Israel and Other Rest of World)

Table of Contents

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

  • 1.1 Product Outline
    • 1.1.1 Biosimilars Defined
    • 1.1.2 Backdrop
    • 1.1.3 The Biologics Price Competition and Innovation Act (BPCI Act)
      • 1.1.3.1 Data Exclusivity
    • 1.1.4 Steps Involved in Biosimilar Synthesis
    • 1.1.5 Key Regulatory Authorization Pathway - Synopsis
    • 1.1.6 Biosimilars Types
      • 1.1.6.1 Monoclonal Antibodies (mAB or moAB)
        • 1.1.6.1.1 Production Process
          • 1.1.6.1.1.1 Hybridoma Cell Production
        • 1.1.6.1.2 Therapeutic Applications
      • 1.1.6.2 Erythropoietin (EPO)
        • 1.1.6.2.1 Functions of EPO
        • 1.1.6.2.2 Mechanism of Action
        • 1.1.6.2.3 Synthesis and Regulation
        • 1.1.6.2.4 Uses in Medicine
      • 1.1.6.3 Granulocyte Colony-Stimulating Factor (G-CSF)
        • 1.1.6.3.1 Biological Function
        • 1.1.6.3.2 Genetics
        • 1.1.6.3.3 Use in Therapeutics
      • 1.1.6.4 Insulin
        • 1.1.6.4.1 Biosimilar Insulin
        • 1.1.6.4.2 The Complexity in Producing Biosimilar Insulin
        • 1.1.6.4.3 Biosimilar Insulins and the Regulatory Environment Surrounding Them
        • 1.1.6.4.4 The Market for Biosimilar Insulins
      • 1.1.6.5 Interferons
        • 1.1.6.5.1 Interferon Categorization
        • 1.1.6.5.2 Functions of Interferons
        • 1.1.6.5.3 Interferon Alfa
        • 1.1.6.5.4 Interferon Beta-1a
        • 1.1.6.5.5 Interferon Gamma
      • 1.1.6.6 Human Growth Hormone
        • 1.1.6.6.1 Recombinant Human Growth Hormone
        • 1.1.6.6.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars
      • 1.1.6.7 Other Biosimilars
    • 1.1.7 Biosimilars Therapeutic Areas
      • 1.1.7.1 Oncology
        • 1.1.7.1.1 Biosimilar G-CSF
      • 1.1.7.2 Autoimmune Diseases
      • 1.1.7.3 Blood Disorders
      • 1.1.7.4 Growth Hormone Deficiency (GHD)
        • 1.1.7.4.1 Growth Hormone Deficiency in Children
      • 1.1.7.5 Infectious Diseases
        • 1.1.7.5.1 Treatment of Infectious Diseases

2. REGULATORY LANDSCAPE

  • 2.1 The United States Food and Drug Administration (USFDA)
    • 2.1.1 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
    • 2.1.2 Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product
    • 2.1.3 Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
  • 2.2 European Medicines Agency (EMA)
  • 2.3 The World Health Organization (WHO)
  • 2.4 Canada
  • 2.5 South Korea
  • 2.6 China
  • 2.7 India
  • 2.8 Japan
  • 2.9 Mexico
  • 2.10 Brazil
  • 2.11 Argentina

3. KEY MARKET TRENDS

  • 3.1 mAbs - All The Rage In Biosimilars' New Wave
    • 3.1.1 The Buildup to the Biosimilar Industry
    • 3.1.2 Current Players: A Sneak Preview
  • 3.2 Biosimilars Slashes the Cancer Treatment Cost
  • 3.3 Emerging Markets to Drive Biosimilars Growth
  • 3.4 Asia: A Preferred Manufacturing Hub for Biosimilars
  • 3.5 SPC Manufacturing Waiver Initiated by EU Commission
  • 3.6 Novel mAb's Purification Approach to Maximize the Biosimilar Production
  • 3.7 Biosimilars and %ldquo;Patent Dance%rdquo;

4. RECENT BIOSIMILARS APPROVALS

5. KEY GLOBAL PLAYERS

  • Adello Biologics (United States)
  • Amgen Inc. (United States)
  • AXXO GmbH (Germany)
  • BIOCAD (Russia)
  • Biogen, Inc. (United States)
  • CoherusBioSciences (United States)
  • Creative BioMart (United States)
  • Dong-A Socio Group (South Korea)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Eli Lilly and Company (United States)
  • Genor Biopharma Co., Ltd. (China)
  • Hetero Drugs Limited (India)
  • Insud Pharma SL (Spain)
  • mAbxience SA (Spain)
  • Intas Pharmaceuticals Ltd. (India)
  • LG Chem (South Korea)
  • Lupin Limited (India)
  • Mylan, Inc (United States)
  • Nippon Kayaku Co., Ltd. (Japan)
  • Pfizer, Inc. (United States)
  • Reliance Life Sciences Pvt. Ltd. (India)
  • Sandoz International GmbH (Germany)
  • Shanghai Henlius Biotech, Inc. (China)
  • STADA Arzneimittel AG (Germany)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Wockhardt Limited (India)
  • Zydus Cadila (India)

6. KEY BUSINESS AND PRODUCT TRENDS

  • Samsung Bioepis Signs Biosimilars Development and Marketing Agreement with C-Bridge Capital
  • Biosimilar Association of Samsung Bioepis and 3SBio
  • Kashiv Pharma Renamed as KashivBioSciences After Acquiring Adello Biologics
  • Japanese Release of Trastuzumab and Agalsidase Beta Biosimilar
  • Epoetin Alfa and Pegfilgrastim Biosimilars Now Accessible In the US at Considerable Concession
  • Biosimilars of Insulin Glargine Introduced in South Korea and the UK
  • CNDA Accepted Review of Adalimumab Biosimilar
  • Filgrastim Biosimilar Application Submitted to the US FDA
  • European Commercial Release of Amgevita and Imraldi
  • MHLW of Japan Received Approval Application for Dual Darbepoetin Alfa Copy Biologics
  • Evaluation of Adalimumab Biosimilar SB5 by USFDA
  • Acceptance of Approval Application by CFDA for Adalimumab Biosimilar
  • Review Acceptance for Mabion CD20 by EMA and Rituxan Expanded the Therapeutic Range
  • Dr Reddy's Introduces Hervycta, A Trastuzumab Biosimilar in India
  • Resubmission of Marketing Approval of Biosimilar Rituximab to FDA by Celltrion
  • Refusal of Trastuzumab and Rituximab Biosimilars Approval Applications by FDA
  • Rejection of Rituximab and Trastuzumab of Celltrion/Teva by FDA
  • Ontruzant Trastuzumab Biosimilar Released in the UK
  • Commercialization of Trastuzumab Biosimilar in South Korea By Daewoong
  • Commercial Release of Adalimumab Biosimilar in India by Hetero
  • Production of Denosumab Biosimilar in Australia
  • Acceptance of Applications for Adalimumab and Trastuzumab by FDA
  • USV's Filing for Pegfilgrastim Accepted by EMA
  • Acceptance of Pegfilgrastim and Trastuzumab Fillings by EMA
  • Introduction of Krabeva, a Bevacizumab Biosimilar, in India
  • Pegfilgrastim Filling Acceptance by EMA
  • Danish Company Appeals FDA for Clinical Studies Data of Victoza Copy Biologics
  • Postponement of Pegfilgrastim Biosimilar Approval of Biocon/Mylan by FDA
  • Acceptance of Pegfilgrastim Biosimilar Filling of Cinfa by EMA
  • The US Commercial Release of Adalimumab Biosimilar of Amgen After January 2023
  • Submission of Approval Application by JCR for Agalsidase Beta Biosimilar in Japan
  • Acceptance of Approval Filing of Filgrastim Biosimilar of Adello by FDA
  • Application Acceptance of Sandoz's Rituximab Biosimilar by FDA
  • Successful Submission of Dual Trastuzumab Biosimilar to the US FDA for Review
  • Biosimilar Business of Merck Taken Over by Fresenius Kabi
  • Merck Introduces RENFLEXIS in the US Market
  • Initiation of Phase III Interchangeability Study of Adalimumab Biosimilar by Boehringer
  • Acceptance of Regulatory Submission for Rituximab Biosimilar of Celltrion/Teva by FDA
  • Refusal of Approval Application of Epoetin Alfa Biosimilar of Pfizer by FDA
  • Registration of Biocad's Rituximab Biosimilars in Honduras and Bolivia
  • Re-evaluation of Bevacizumab and Trastuzumab by FDA Advisory Board
  • Rejection of Pegfilgrastim Biosimilar of Coherus by FDA
  • EMA Acceptance of Sandoz's Adalimumab and Infliximab Biosimilars for Re-evaluation
  • Epoetin Alfa of Pfizer Receives Approval Recommendation from FDA Advisors
  • Approval Application Acceptance of Fujifilm's Adalimumab Biosimilar by EMA
  • Australian Commercial Release of Infliximab Biosimilar in Second half of 2017
  • Submission of Approval Application in Japan for Trastuzumab Biosimilar
  • Introduction of Basal Analogue Insulin Biosimilar in Indonesia
  • Acceptance of Pegfilgrastim Filling of Mylan/Biocon by FDA
  • Japanese Approval Application Filed for Etanercept Biosimilar
  • Filing of Biosimilar Adalimumab Application by Boehringer to FDA and EMA As Well
  • Withdrawal of Biosimilar Pegfilgrastim Application by Sandoz

7. GLOBAL MARKET OVERVIEW

  • 7.1 Global Biosimilars Market Overview by Product Type
    • 7.1.1 Global Biosimilars Product Types Market Overview by Geographic Region
      • 7.1.1.1 Monoclonal Antibodies
      • 7.1.1.2 Erythropoietin
      • 7.1.1.3 G-CSF
      • 7.1.1.4 Insulin
      • 7.1.1.5 Other Product Types
  • 7.2 Global Biosimilars Market Overview by Therapeutic Area
    • 7.2.1 Global Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 7.2.1.1 Oncology
      • 7.2.1.2 Autoimmune Disorders
      • 7.2.1.3 Blood Disorders
      • 7.2.1.4 Growth Hormone Deficiency
      • 7.2.1.5 Other Therapeutic Areas

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

8. EUROPE

  • 8.1 European Biosimilars Market Overview by Geographic Region
  • 8.2 European Biosimilars Market Overview by Product Type
    • 8.2.1 European Biosimilars Product Types Market Overview by Geographic Region
      • 8.2.1.1 Monoclonal Antibodies
      • 8.2.1.2 Erythropoietin
      • 8.2.1.3 G-CSF
      • 8.2.1.4 Insulin
      • 8.2.1.5 Other Product Types
  • 8.3 European Biosimilars Market Overview by Therapeutic Area
    • 8.3.1 European Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 8.3.1.1 Oncology
      • 8.3.1.2 Autoimmune Disorders
      • 8.3.1.3 Blood Disorders
      • 8.3.1.4 Growth Hormone Deficiency
      • 8.3.1.5 Other Therapeutic Areas
  • 8.4 Major Market Players
    • Alvotech (Iceland)
    • AXXO GmbH (Germany)
    • BIOCAD (Russia)
    • Insud Pharma SL (Spain)
    • mAbxience SA (Spain)
    • Sandoz International GmbH (Germany)
    • STADA Arzneimittel AG (Germany)
    • UGA Biopharma GmbH (Germany)
  • 8.5 Country-wise analysis of European Biosimilars Market
    • 8.5.1 Germany
      • 8.5.1.1 German Biosimilars Market Overview by Product Type
      • 8.5.1.2 German Biosimilars Market Overview by Therapeutic Area
    • 8.5.2 United Kingdom
      • 8.5.2.1 United Kingdom Biosimilars Market Overview by Product Type
      • 8.5.2.2 United Kingdom Biosimilars Market Overview by Therapeutic Area
    • 8.5.3 France
      • 8.5.3.1 French Biosimilars Market Overview by Product Type
      • 8.5.3.2 French Biosimilars Market Overview by Therapeutic Area
    • 8.5.4 Spain
      • 8.5.4.1 Spanish Biosimilars Market Overview by Product Type
      • 8.5.4.2 Spanish Biosimilars Market Overview by Therapeutic Area
    • 8.5.5 Italy
      • 8.5.5.1 Italian Biosimilars Market Overview by Product Type
      • 8.5.5.2 Italian Biosimilars Market Overview by Therapeutic Area
    • 8.5.6 Rest of Europe
      • 8.5.6.1 Rest of Europe Biosimilars Market Overview by Product Type
      • 8.5.6.2 Rest of Europe Biosimilars Market Overview by Therapeutic Area

9. NORTH AMERICA

  • 9.1 North American Biosimilars Market Overview by Geographic Region
  • 9.2 North American Biosimilars Market Overview by Product Type
    • 9.2.1 North American Biosimilars Product Types Market Overview by Geographic Region
      • 9.2.1.1 Monoclonal Antibodies
      • 9.2.1.2 Erythropoietin
      • 9.2.1.3 G-CSF
      • 9.2.1.4 Insulin
      • 9.2.1.5 Other Product Types
  • 9.3 North American Biosimilars Market Overview by Therapeutic Area
    • 9.3.1 North American Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 9.3.1.1 Oncology
      • 9.3.1.2 Autoimmune Disorders
      • 9.3.1.3 Blood Disorders
      • 9.3.1.4 Growth Hormone Deficiency
      • 9.3.1.5 Other Therapeutic Areas
  • 9.4 Major Market Players
    • Adello Biologics (United States)
    • Amgen Inc. (United States)
    • Biogen, Inc. (United States)
    • CoherusBioSciences(United States)
    • Creative BioMart(United States)
    • Eli Lilly and Company (United States)
    • Harvest Moon Pharmaceuticals USA, Inc. (United States)
    • Momenta Pharmaceuticals Inc. (United States)
    • Mylan, Inc (United States)
    • Pfizer, Inc. (United States)
  • 9.5 Country-wise Analysis of North American Biosimilars Market
    • 9.5.1 The United States
      • 9.5.1.1 United States Biosimilars Market Overview by Product Type
      • 9.5.1.2 United States Biosimilars Market Overview by Therapeutic Area
    • 9.5.2 Canada
      • 9.5.2.1 Canadian Biosimilars Market Overview by Product Type
      • 9.5.2.2 Canadian Biosimilars Market Overview by Therapeutic Area
    • 9.5.3 Mexico
      • 9.5.3.1 Mexican Biosimilars Market Overview by Product Type
      • 9.5.3.2 Mexican Biosimilars Market Overview by Therapeutic Area

10. ASIA-PACIFIC

  • 10.1 Asia-Pacific Biosimilars Market Overview by Geographic Region
  • 10.2 Asia-Pacific Biosimilars Market Overview by Product Type
    • 10.2.1 Asia-Pacific Biosimilars Product Types Market Overview by Geographic Region
      • 10.2.1.1 Monoclonal Antibodies
      • 10.2.1.2 Erythropoietin
      • 10.2.1.3 G-CSF
      • 10.2.1.4 Insulin
      • 10.2.1.5 Other Product Types
  • 10.3 Asia-Pacific Biosimilars Market Overview by Therapeutic Area
    • 10.3.1 Asia-Pacific Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 10.3.1.1 Oncology
      • 10.3.1.2 Autoimmune Disorders
      • 10.3.1.3 Blood Disorders
      • 10.3.1.4 Growth Hormone Deficiency
      • 10.3.1.5 Other Therapeutic Areas
  • 10.4 Major Market Players
    • 3SBIO, Inc (China)
    • Biocon Limited (India)
    • Biogenomics Limited (India)
    • Bioviz Technologies Pvt. Ltd. (India)
    • Celltrion, Inc. (South Korea)
    • Dong-A Socio Group (South Korea)
    • Dr. Reddy's Laboratories Ltd. (India)
    • Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
    • Genor Biopharma Co., Ltd. (China)
    • Hetero Drugs Limited (India)
    • Intas Pharmaceuticals Ltd (India)
    • LG Chem (South Korea)
    • Lupin Limited (India)
    • Nippon Kayaku Co., Ltd. (Japan)
    • Reliance Life Sciences Pvt. Ltd. (India)
    • Samsung Bioepis Co., Ltd. (South Korea)
    • SciGen Pte. Ltd. (Singapore)
    • Shanghai Henlius Biotech, Inc. (China)
    • Siam Bioscience Co., Ltd. (Thailand)
    • Wockhardt Limited (India)
    • YL Biologics Limited (Japan)
    • Zydus Cadila (India)
  • 10.5 Country-wise Analysis of Asia-Pacific Biosimilars Market
    • 10.5.1 China
      • 10.5.1.1 Chinese Biosimilars Market Overview by Product Type
      • 10.5.1.2 Chinese Biosimilars Market Overview by Therapeutic Area
    • 10.5.2 India
      • 10.5.2.1 Indian Biosimilars Market Overview by Product Type
      • 10.5.2.2 Indian Biosimilars Market Overview by Therapeutic Area
    • 10.5.3 Japan
      • 10.5.3.1 Japanese Biosimilars Market Overview by Product Type
      • 10.5.3.2 Japanese Biosimilars Market Overview by Therapeutic Area
    • 10.5.4 South Korea
      • 10.5.4.1 South Korean Biosimilars Market Overview by Product Type
      • 10.5.4.2 South Korean Biosimilars Market Overview by Therapeutic Area
    • 10.5.5 Rest of Asia-Pacific
      • 10.5.5.1 Rest of Asia-Pacific Biosimilars Market Overview by Product Type
      • 10.5.5.12 Rest of Asia-Pacific Biosimilars Market Overview by Therapeutic Area

11. REST OF WORLD

  • 11.1 Rest of World Biosimilars Market Overview by Geographic Region
  • 11.2 Rest of World Biosimilars Market Overview by Product Type
    • 11.2.1 Rest of World Biosimilars Product Types Market Overview by Geographic Region
      • 11.2.1.1 Monoclonal Antibodies
      • 11.2.1.2 Erythropoietin
      • 11.2.1.3 G-CSF
      • 11.2.1.4 Insulin
      • 11.2.1.5 Other Product Types
  • 11.3 Rest of World Biosimilars Market Overview by Therapeutic Area
    • 11.3.1 Rest of World Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 11.3.1.1 Oncology
      • 11.3.1.2 Autoimmune Disorders
      • 11.3.1.3 Blood Disorders
      • 11.3.1.4 Growth Hormone Deficiency
      • 11.3.1.5 Other Therapeutic Areas
  • 11.4 Major Market Players
    • AMEGA Biotech (Argentina)
    • Teva Pharmaceutical Industries Limited (Israel)
  • 11.5 Country-wise Analysis of Rest of World Biosimilars Market
    • 11.5.1 Brazil
      • 11.5.1.1 Brazilian Biosimilars Market Overview by Product Type
      • 11.5.1.2 Brazilian Biosimilars Market Overview by Therapeutic Area
    • 11.5.2 Israel
      • 11.5.2.1 Israeli Biosimilars Market Overview by Product Type
      • 11.5.2.2 Israeli Biosimilars Market Overview by Therapeutic Area
    • 11.5.3 Other Countries
      • 11.5.3.1 Other Countries Biosimilars Market Overview by Product Type
      • 11.5.3.2 Other Countries Biosimilars Market Overview by Therapeutic Area

PART C: GUIDE TO THE INDUSTRY

  • 1. NORTH AMERICA
  • 2. EUROPE
  • 3. ASIA-PACIFIC
  • 4. REST OF WORLD

PART D: ANNEXURE

  • 1. RESEARCH METHODOLOGY
  • 2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

  • Chart 1: Global Biosimilars Market (2018 & 2025) by Geographic Region
  • Chart 2: Global Biosimilars Market (2018 & 2025) by Product Type
  • Chart 3: Global Biosimilars Market (2018 & 2025) by Therapeutic Areas
  • Chart 4: Global Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 5: Global Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 6: Glance at 2016, 2019 and 2025 Global Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 7: Global Biosimilar Monoclonal Antibodies Market Analysis (2016-2025) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in USD Million
  • Chart 8: Glance at 2016, 2019 and 2025 Global Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 9: Global Biosimilar Erythropoietin Market Analysis (2016-2025) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 10: Glance at 2016, 2019 and 2025 Global Biosimilar Erythropoietin Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 11: Global Biosimilar G-CSF Market Analysis (2016-2025) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 12: Glance at 2016, 2019 and 2025 Global Biosimilar G-CSF Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 13: Global Biosimilar Insulin Market Analysis (2016-2025) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 14: Glance at 2016, 2019 and 2025 Global Biosimilar Insulin Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 15: Global Other Biosimilar Product Types Market Analysis (2016-2025) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 16: Glance at 2016, 2019 and 2025 Global Other Biosimilar Products Types Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 17: Global Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 18: Glance at 2016, 2019 and 2025 Global Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 19: Global Biosimilars Market Analysis (2016-2025) in Oncology by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 20: Glance at 2016, 2019 and 2025 Global Biosimilars Market Share (%) in Oncology by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 21: Global Biosimilars Market Analysis (2016-2025) in Autoimmune Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 22: Glance at 2016, 2019 and 2025 Global Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 23: Global Biosimilars Market Analysis (2016-2025) in Blood Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 24: Glance at 2016, 2019 and 2025 Global Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 25: Global Biosimilars Market Analysis (2016-2025) in Growth Hormone Deficiency by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 26: Glance at 2016, 2019 and 2025 Global Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 27: Global Biosimilars Market Analysis (2016-2025) in Other Therapeutic Areas by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 28: Glance at 2016, 2019 and 2025 Global Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

  • Chart 29: Global Biosimilars Market Analysis (2016-2025) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in USD Million
  • Chart 30: Glance at 2016, 2019 and 2025 Global Biosimilars Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

REGIONAL MARKET OVERVIEW

EUROPE

  • Chart 31: European Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 32: European Biosimilars Market Analysis (2016-2025) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in USD Million
  • Chart 33: Glance at 2016, 2019 and 2025 European Biosimilars Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 34: European Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 35: Glance at 2016, 2019 and 2025 European Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 36: European Biosimilar Monoclonal Antibodies Market Analysis (2016-2025) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in USD Million
  • Chart 37: Glance at 2016, 2019 and 2025 European Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 38: European Biosimilar Erythropoietin Market Analysis (2016-2025) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 39: Glance at 2016, 2019 and 2025 European Biosimilar Erythropoietin Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 40: European Biosimilar G-CSF Market Analysis (2016-2025) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 41: Glance at 2016, 2019 and 2025 European Biosimilar G-CSF Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 42: European Biosimilar Insulin Market Analysis (2016-2025) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 43: Glance at 2016, 2019 and 2025 European Biosimilar Insulin Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 44: European Other Biosimilar Product Types Market Analysis (2016-2025) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 45: Glance at 2016, 2019 and 2025 European Other Biosimilar Products Types Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 46: European Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 47: Glance at 2016, 2019 and 2025 European Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 48: European Biosimilars Market Analysis (2016-2025) in Oncology by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 49: Glance at 2016, 2019 and 2025 European Biosimilars Market Share (%) in Oncology by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 50: European Biosimilars Market Analysis (2016-2025) in Autoimmune Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 51: Glance at 2016, 2019 and 2025 European Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 52: European Biosimilars Market Analysis (2016-2025) in Blood Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 53: Glance at 2016, 2019 and 2025 European Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 54: European Biosimilars Market Analysis (2016-2025) in Growth Hormone Deficiency by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 55: Glance at 2016, 2019 and 2025 European Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 56: European Biosimilars Market Analysis (2016-2025) in Other Therapeutic Areas by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 57: Glance at 2016, 2019 and 2025 European Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Germany

  • Chart 58: German Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 59: German Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 60: Glance at 2016, 2019 and 2025 German Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 61: German Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 62: Glance at 2016, 2019 and 2025 German Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

United Kingdom

  • Chart 63: United Kingdom Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 64: United Kingdom Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 65: Glance at 2016, 2019 and 2025 United Kingdom Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 66: United Kingdom Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 67: Glance at 2016, 2019 and 2025 United Kingdom Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

France

  • Chart 68: French Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 69: French Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 70: Glance at 2016, 2019 and 2025 French Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 71: French Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 72: Glance at 2016, 2019 and 2025 French Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Spain

  • Chart 73: Spanish Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 74: Spanish Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 75: Glance at 2016, 2019 and 2025 Spanish Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 76: Spanish Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 77: Glance at 2016, 2019 and 2025 Spanish Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Italy

  • Chart 78: Italian Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 79: Italian Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 80: Glance at 2016, 2019 and 2025 Italian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 81: Italian Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 82: Glance at 2016, 2019 and 2025 Italian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Rest of Europe

  • Chart 83: Rest of Europe Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 84: Rest of Europe Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 85: Glance at 2016, 2019 and 2025 Rest of Europe Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 86: Rest of Europe Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 87: Glance at 2016, 2019 and 2025 Rest of Europe Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

NORTH AMERICA

  • Chart 88: North American Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 89: North American Biosimilars Market Analysis (2016-2025) by Geographic Region - United States, Canada and Mexico in USD Million
  • Chart 90: Glance at 2016, 2019 and 2025 North American Biosimilars Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 91: North American Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 92: Glance at 2016, 2019 and 2025 North American Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 93: North American Biosimilar Monoclonal Antibodies Market Analysis (2016-2025) by Geographic Region - United States, Canada and Mexico in USD Million
  • Chart 94: Glance at 2016, 2019 and 2025 North American Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 95: North American Biosimilar Erythropoietin Market Analysis (2016-2025) by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 96: Glance at 2016, 2019 and 2025 North American Biosimilar Erythropoietin Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 97: North American Biosimilar G-CSF Market Analysis (2016-2025) by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 98: Glance at 2016, 2019 and 2025 North American Biosimilar G-CSF Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 99: North American Biosimilar Insulin Market Analysis (2016-2025) by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 100: Glance at 2016, 2019 and 2025 North American Biosimilar Insulin Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 101: North American Other Biosimilar Product Types Market Analysis (2016-2025) by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 102: Glance at 2016, 2019 and 2025 North American Other Biosimilar Products Types Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 103: North American Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 104: Glance at 2016, 2019 and 2025 North American Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 105: North American Biosimilars Market Analysis (2016-2025) in Oncology by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 106: Glance at 2016, 2019 and 2025 North American Biosimilars Market Share (%) in Oncology by Geographic Region - United States, Canada and Mexico
  • Chart 107: North American Biosimilars Market Analysis (2016-2025) in Autoimmune Disorders by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 108: Glance at 2016, 2019 and 2025 North American Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - United States, Canada and Mexico
  • Chart 109: North American Biosimilars Market Analysis (2016-2025) in Blood Disorders by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 110: Glance at 2016, 2019 and 2025 North American Biosimilars Market Share (%) in Blood Disorders by Geographic Region - United States, Canada and Mexico
  • Chart 111: North American Biosimilars Market Analysis (2016-2025) in Growth Hormone Deficiency by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 112: Glance at 2016, 2019 and 2025 North American Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - United States, Canada and Mexico
  • Chart 113: North American Biosimilars Market Analysis (2016-2025) in Other Therapeutic Areas by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 114: Glance at 2016, 2019 and 2025 North American Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - United States, Canada and Mexico

The United States

  • Chart 115: United States Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 116: United States Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 117: Glance at 2016, 2019 and 2025 United States Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 118: United States Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 119: Glance at 2016, 2019 and 2025 United States Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Canada

  • Chart 120: Canadian Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 121: Canadian Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 122: Glance at 2016, 2019 and 2025 Canadian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 123: Canadian Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 124: Glance at 2016, 2019 and 2025 Canadian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Mexico

  • Chart 125: Mexican Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 126: Mexican Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 127: Glance at 2016, 2019 and 2025 Mexican Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 128: Mexican Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 129: Glance at 2016, 2019 and 2025 Mexican Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

ASIA-PACIFIC

  • Chart 130: Asia-Pacific Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 131: Asia-Pacific Biosimilars Market Analysis (2016-2025) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in USD Million
  • Chart 132: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilars Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 133: Asia-Pacific Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 134: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 135: Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis (2016-2025) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in USD Million
  • Chart 136: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 137: Asia-Pacific Biosimilar Erythropoietin Market Analysis (2016-2025) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 138: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilar Erythropoietin Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 139: Asia-Pacific Biosimilar G-CSF Market Analysis (2016-2025) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 140: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilar G-CSF Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 141: Asia-Pacific Biosimilar Insulin Market Analysis (2016-2025) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 142: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilar Insulin Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 143: Asia-Pacific Other Biosimilar Product Types Market Analysis (2016-2025) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 144: Glance at 2016, 2019 and 2025 Asia-Pacific Other Biosimilar Products Types Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 145: Asia-Pacific Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 146: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 147: Asia-Pacific Biosimilars Market Analysis (2016-2025) in Oncology by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 148: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilars Market Share (%) in Oncology by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 149: Asia-Pacific Biosimilars Market Analysis (2016-2025) in Autoimmune Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 150: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 151: Asia-Pacific Biosimilars Market Analysis (2016-2025) in Blood Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 152: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilars Market Share (%) in Blood Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 153: Asia-Pacific Biosimilars Market Analysis (2016-2025) in Growth Hormone Deficiency by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 154: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 155: Asia-Pacific Biosimilars Market Analysis (2016-2025) in Other Therapeutic Areas by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 156: Glance at 2016, 2019 and 2025 Asia-Pacific Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

China

  • Chart 157: Chinese Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 158: Chinese Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 159: Glance at 2016, 2019 and 2025 Chinese Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 160: Chinese Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 161: Glance at 2016, 2019 and 2025 Chinese Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

India

  • Chart 162: Indian Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 163: Indian Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 164: Glance at 2016, 2019 and 2025 Indian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 165: Indian Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 166: Glance at 2016, 2019 and 2025 Indian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Japan

  • Chart 167: Japanese Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 168: Japanese Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 169: Glance at 2016, 2019 and 2025 Japanese Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 170: Japanese Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 171: Glance at 2016, 2019 and 2025 Japanese Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

South Korea

  • Chart 172: South Korean Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 173: South Korean Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 174: Glance at 2016, 2019 and 2025 South Korean Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 175: South Korean Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 176: Glance at 2016, 2019 and 2025 South Korean Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Rest of Asia-Pacific

  • Chart 177: Rest of Asia-Pacific Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 178: Rest of Asia-Pacific Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 179: Glance at 2016, 2019 and 2025 Rest of Asia-Pacific Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 180: Rest of Asia-Pacific Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 181: Glance at 2016, 2019 and 2025 Rest of Asia-Pacific Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

REST OF WORLD

  • Chart 182: Rest of World Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 183: Rest of World Biosimilars Market Analysis (2016-2025) by Geographic Region - Brazil, Israel and Other Countries in USD Million
  • Chart 184: Glance at 2016, 2019 and 2025 Rest of World Biosimilars Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 185: Rest of World Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 186: Glance at 2016, 2019 and 2025 Rest of World Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 187: Rest of World Biosimilar Monoclonal Antibodies Market Analysis (2016-2025) by Geographic Region - Brazil, Israel and Other Countries in USD Million
  • Chart 188: Glance at 2016, 2019 and 2025 Rest of World Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 189: Rest of World Biosimilar Erythropoietin Market Analysis (2016-2025) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 190: Glance at 2016, 2019 and 2025 Rest of World Biosimilar Erythropoietin Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 191: Rest of World Biosimilar G-CSF Market Analysis (2016-2025) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 192: Glance at 2016, 2019 and 2025 Rest of World Biosimilar G-CSF Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 193: Rest of World Biosimilar Insulin Market Analysis (2016-2025) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 194: Glance at 2016, 2019 and 2025 Rest of World Biosimilar Insulin Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 195: Rest of World Other Biosimilar Product Types Market Analysis (2016-2025) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 196: Glance at 2016, 2019 and 2025 Rest of World Other Biosimilar Products Types Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 197: Rest of World Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 198: Glance at 2016, 2019 and 2025 Rest of World Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 199: Rest of World Biosimilars Market Analysis (2016-2025) in Oncology by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 200: Glance at 2016, 2019 and 2025 Rest of World Biosimilars Market Share (%) in Oncology by Geographic Region - Brazil, Israel and Other Countries
  • Chart 201: Rest of World Biosimilars Market Analysis (2016-2025) in Autoimmune Disorders by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 202: Glance at 2016, 2019 and 2025 Rest of World Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Brazil, Israel and Other Countries
  • Chart 203: Rest of World Biosimilars Market Analysis (2016-2025) in Blood Disorders by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 204: Glance at 2016, 2019 and 2025 Rest of World Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Brazil, Israel and Other Countries
  • Chart 205: Rest of World Biosimilars Market Analysis (2016-2025) in Growth Hormone Deficiency by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 206: Glance at 2016, 2019 and 2025 Rest of World Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Brazil, Israel and Other Countries
  • Chart 207: Rest of World Biosimilars Market Analysis (2016-2025) in Other Therapeutic Areas by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 208: Glance at 2016, 2019 and 2025 Rest of World Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Brazil, Israel and Other Countries

Brazil

  • Chart 209: Brazilian Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 210: Brazilian Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 211: Glance at 2016, 2019 and 2025 Brazilian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 212: Brazilian Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 213: Glance at 2016, 2019 and 2025 Brazilian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Israel

  • Chart 214: Israeli Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 215: Israeli Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 216: Glance at 2016, 2019 and 2025 Israeli Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 217: Israeli Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 218: Glance at 2016, 2019 and 2025 Israeli Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Other Countries

  • Chart 219: Other Countries Biosimilars Market Analysis (2016-2025) in USD Million
  • Chart 220: Other Countries Biosimilars Market Analysis (2016-2025) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 221: Glance at 2016, 2019 and 2025 Other Countries Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 222: Other Countries Biosimilars Market Analysis (2016-2025) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 223: Glance at 2016, 2019 and 2025 Other Countries Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Tables:

  • Table 1: Biosimilar Synonyms
  • Table 2: Comparison of Generics and Biosimilars
  • Table 3: List of the US and European Approved Biosimilars for Diabetes
  • Table 4: List of the US and European Approved Biosimilars for Oncology
  • Table 5: List of the US and European Approved Biosimilars for Autoimmune Disorders
  • Table 6: List of the US and European Approved Biosimilars for Blood Disorders
  • Table 7: List of the US and European Approved Biosimilars for Other Indications
  • Table 8: List of Leading Bioloigcs Containing mAbs, Year of Approval and Patent Expiry in Europe and the United States
  • Table 9: Number of Biosimilar mAbs in Pipeline
  • Table 10: Global Biosimilar Pipeline and its Manufacturer
  • Table 11: Biosimilars Approvals from 2017 to 2019
Back to Top